Novartis International AG / Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for...
Source : http://www.romandie.com/news/Novartis-Internationa...
Source : http://www.romandie.com/news/Novartis-Internationa...